To further confirm this hypothesis, we checked the IC50 of cells directly after silencing CPT1A with siRNA or etomoxir and it showed that blocking CPT1A reversed oxaliplatin resistance in colon cancer, which could be a novel method for reversal of oxaliplatin resistance. This evidence concerns the gene CPT1A and malignant colon neoplasm.